Aktuellt
SENASTE
Redeye is making some downward revisions in our forecasts and valuation but still sees an interesting potential in the share. Market conditions continue to be somewhat sluggish and Q3 sales were to some extent impacted by delays in shipments. Heliospectra is optimistic about the launch of the new biosensors in 2022, which it sees as the start of a completely new phase. Integrated sensors will probably be a major long-term growth driver for the company. We are lowering our near-term estimates and include an anticipated future rights issue in our valuation. Our new Base case fair value is just over SEK 3 per share.
LÄS MER
